Análisis Argos
KRYS
KRYSCara
Krystal Biotech, Inc. · Healthcare
US$ 375.07
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
55/100
LA RESPUESTA
El mercado le pide crezca 51% al año — más de lo que ha demostrado (18%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Las ganancias crecieron 130% el último año.
✓Retorno sobre el capital alto (22%).
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Venta significativa de insiders en el último trimestre.
VALOR1/6FUTURO6/6PASADO5/6SALUD6/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO6/6PASADO5/6SALUD6/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoEl dividendo aún duerme
Score Argos55de 100Cara
Ingresos▲34%
US$ 0.4 B
Margen operativo▲84%
41.5%
Flujo de caja libre▲58%
US$ 0.2 B
Deuda neta
US$ -0.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 11.1B
P/E54x
EV/EBITDA63x
FCF yield1.7%
ROIC22%
Margen operativo41.5%
Crecim. ingresos+33.9%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 29 jun
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
investors.com · 26 jun
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
marketbeat.com · 23 jun
3 Biotech Firms With Major Potential Catalysts in the Coming Months
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
marketbeat.com · 21 jun
3 Biotech Firms With Major Potential Catalysts in the Coming Months
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
fool.com · 18 jun
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
zacks.com · 5 jun
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
zacks.com · 4 jun
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
zacks.com · 3 jun
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.